DynPort Vaccine Company LLC

CourtArmed Services Board of Contract Appeals
DecidedJanuary 15, 2015
DocketASBCA No. 59298
StatusPublished

This text of DynPort Vaccine Company LLC (DynPort Vaccine Company LLC) is published on Counsel Stack Legal Research, covering Armed Services Board of Contract Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
DynPort Vaccine Company LLC, (asbca 2015).

Opinion

ARMED SERVICES BOARD OF CONTRACT APPEALS

Appeal of -- ) ) DynPort Vaccine Company LLC ) ASBCA No. 59298 ) Under Contract No. DAMDl 7-98-C-8024 )

APPEARANCE FOR THE APPELLANT: Carl J. Peckinpaugh, Esq. Counsel Computer Sciences Corporation Falls Church, VA

APPEARANCES FOR THE GOVERNMENT: Raymond M. Saunders, Esq. Army Chief Trial Attorney Kyle E. Chadwick, Esq. Trial Attorney

OPINION BY ADMINISTRATIVE JUDGE JAMES ON THE GOVERNMENT'S MOTION TO DISMISS FOR LACK OF JURISDICTION

The contracting officer's (CO's) unilateral contract modification directed appellant to perform corrective or replacement work at no cost to the government pursuant to the contract's FAR 52.246-8, INSPECTION OF RESEARCH AND DEVELOPMENT - COST-REIMBURSEMENT (APR 1984) clause. Appellant appealed from the issuance of that modification. The government moves to dismiss the appeal for lack of jurisdiction under the Contract Disputes Act (CDA), 41 U.S.C. §§ 7101-7109, on the ground that such modification did not assert a government claim. Appellant opposed the motion and requested that the government file the first pleading. The government replied. We deny the motion and grant appellant's request.

STATEMENT OF FACTS (SOF) FOR PURPOSES OF THE MOTION

1. On 7 November 1997. the U.S. Army Medical Research Acquisition Activity, on behalf of the Department of Defense Joint Vaccine Acquisition Program, awarded Contract No. DAMDl 7-98-C-8024 (the contract), a cost-reimbursement, cost sharing, award fee research and development type contract to ·'DynPort, LLC" 1 for, inter alia, the development and licensure application of vaccines and other biological defense products (gov't mot., ex. G-1 at 1-3, 302 ). Under contract line item number (CLIN) 0016, DVC was required, on a cost-plus-award-fee basis, to develop and test

1 Modification No. P00354 was issued to DynPort Vaccine Company, LLC (DVC) (gov't mot., ex. G-2). DVC is a wholly-owned subsidiary of Computer Sciences Corporation (app. opp'n, ex. A, Pandey decl. (Pandey decl.) iJ 1). 2 Citations to pages in exhibits G-1, -3 and -4 are to their Bates numbers. for FDA licensure application serotypes of a botulinum (BOT) vaccine (gov't mot. i-f 1, ex. G-1at10-11; Pandey decl. ~ 2).

2. The contract incorporates by reference the FAR 52.233-1, DISPUTES (OCT 1995) - AL TERNA TE I (DEC 1991) clause, which provides, in pertinent part:

( c) Claim, as used in this clause, means a written demand or written assertion by one of the contracting parties seeking, as a matter of right, the payment of money in a sum certain, the adjustment or interpretation of contract terms, or other relief arising under or relating to this contract. ...

(d)( 1) ... A claim by the Government against the Contractor shall be subject to a written decision by the Contracting Officer.

(i) The Contractor shall proceed diligently with performance of this contract, pending final resolution of any request for relief. claim. appeal, or action arising under the contract, and comply with any decision of the Contracting Officer.

(Gov't mot., ex. G-1 at 61)

3. The contract also incorporated by reference the FAR 52.246-8, INSPECTION OF RESEARCH AND DEVELOPMENT- COST-REIMBURSEMENT (APR 1984) clause, which provides, in pertinent part:

( f) At any time during contract performance, but no later than 6 months (or such other time as may be specified in the contract) after acceptance of all the end items (other than designs, drawings, or reports) to be delivered under the contract, the Government may require the Contractor to replace or correct work not meeting contract requirements. Time devoted to the replacement or correction of such work shall not be included in the computation of the above time period. Except as otherwise provided in paragraph (h) below, the cost of replacement or correction shall be determined as specified in the Allowable Cost and Payment clause, but no additional fee shall be paid. The Contractor shall not tender for acceptance work required to

2 be replaced or corrected without disclosing the former requirement for replacement or correction, and when required, shall disclose the corrective action taken.

(g) (I) If the Contractor fails to proceed with reasonable promptness to perform required replacement or correction the Government may-

(i) By contract or otherwise, perform the replacement or correction, charge to the Contractor any increased cost, or make an equitable reduction in any fixed fee paid or payable under the contract;

(ii) Require delivery of any undelivered articles and shall have the right to make an equitable reduction in any fixed fee paid or payable under the contract; or

(iii) Terminate the contract for default.

(2) Failure to agree on the amount of increased cost to be charged the Contractor or to the reduction in fixed fee shall be a dispute.

(h) Notwithstanding paragraphs (f) and (g) above, the Government may at any time require the Contractor to remedy by correction or replacement, without cost to the Government, any failure by the Contractor to comply with the requirements of this contract, if the failure is due to (I) fraud, lack of good faith. or willful misconduct on the part of the Contractor's managerial personnel or (2) the conduct of one or more of the Contractor's employees selected or retained by the Contractor after any of the Contractor's managerial personnel has reasonable grounds to believe that the employee is habitually careless or unqualified.

(Gov't mot., ex. G-1 at 37)

4. On 7 February 2012 bilateral Modification No. P00354 established a delivery date of July 2016 for the CLIN 0016 vaccines (gov't mot.~ 1, ex. G-2 at 3).

5. On 23 August 2013 DVC terminated for default its subcontractor, Lonza Hopkinton, Inc., for BOT antigens under CLIN 0016 (gov't mot.~ 3, ex. G-3 at 3; Pandey decl. ~ 4 ).

3 6. DVC's 14 November 2013 letter to CO Lawrence Mize proposed a change order to add subcontractor FUJIFILM Diosynth Biotechnologies, U.S.A., LLC (FDBU) to complete CLIN 0016 BOT Antigen A and Antigen B manufacturing, testing and two technology transfer studies for $4,071, 175 ($4,629,326.19 with DVC markup). DVC stated that such studies were required to complete manufacturing processes and testing of the vaccine product for Ii censure and readiness for commercial production due to the impact caused by the Lonza termination. DVC requested a contract modification incorporating the proposed new work on or before 13 December 2013. (Gov't mot., ex. G-3 at 1, 3-5, 10)

7. On 15 November 2013, when the parties met to discuss DVC's change proposal, the government told DVC that it did not believe DVC was entitled to reimbursement of its proposed technology transfer costs (gov't mot. ~ 6, ex. G-4 at 1; Pandey decl. ~ 6 ).

8. DVC's 26 November 2013 letter to CO Mize stated that DVC was entitled to an increase in the contract cost for the proposed studies, such cost was allowable and reimbursable, under the contract the government had previously reimbursed DVC for technology transfer costs for performance-related issues, the shutdown of Lonza's facilities was unknown and unpreventable, and DVC had expended its best efforts to meet contractual requirements (gov't mot., ex. G-4 ).

9. CO Mize's 20 January 2014 letter responded to DVC's 26 November 2013 letter and asserted that the government was not liable for increased costs due to DVC's "carelessness in its conduct of the work or the degree of its disregard of contractual duties" (gov't mot., ex. G-5, ~ 1).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
DynPort Vaccine Company LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dynport-vaccine-company-llc-asbca-2015.